$ALECNeutralLow

Berkley Neil Lindsay sold $38K of ALEC

Berkley Neil Lindsay (CFO & Chief Business Officer) sold 19,360 shares of Alector, Inc. (ALEC) at $1.97 on 2026-06-02.

6/10
6/10
Low
Neutral
Filed/visible after-hours on 2026-06-03; sale occurred 2026-06-02.
Neutral to slightly negative (insider selling), but not a fundamental reset.

Insider selling is a near-term sentiment signal, but this specific sale is not tied to a 10b5-1 plan and may reflect diversification or liquidity needs.

Alector CFO/Chief Business Officer Berkley Neil Lindsay sold 19,360 shares in an open-market transaction disclosed on Form 4.

Likely limited and short-lived; any impact would be sentiment-driven rather than fundamental.

Background

This is an SEC Form 4 insider transaction disclosure for Alector, Inc. (ALEC).

Why it matters

The disclosure may slightly influence short-term sentiment, but it does not introduce new operational or clinical information about Alector.

Market relevance

Traders may monitor for subsequent insider buying/selling patterns, but the filing alone is unlikely to drive a durable repricing.

Market effects

Minimal; single-company insider transaction without sector-wide signal.

None indicated.

None indicated.

Alternative perspectives

Because the sale is not disclosed as 10b5-1, it could be routine diversification rather than a bearish view on fundamentals.

Insider sales often occur for tax/liquidity reasons; without follow-on purchases or broader insider activity, the signal is weak.

Key entities

  • Alector, Inc.

    Subject of the Form 4 insider sale by its CFO & Chief Business Officer.

  • Berkley Neil Lindsay

    CFO & Chief Business Officer who sold 19,360 shares at $1.9742 on 2026-06-02.

Related articles

$ALECMedAI 8/10

UAE Business: ALEC unit Target wins $500m three EPC contracts in Gulf

ALEC Holdings said its subsidiary Target Engineering Construction Company – SP won three Gulf EPC contracts totaling over $500 million, according to a filing to the Dubai Stock Market. The projects have execution periods of 10, 21 and 36 months. ALEC said the awards’ financial impact will be recognized over those periods under its revenue policy, and it did not name clients, locations or scope.

$ALECLow

Alector (NASDAQ: ALEC) Q1 2026 results, trial halt and ABC focus

Alector (NASDAQ: ALEC) reported its Q1 2026 financial results, revealing a narrowed net loss of $22.9 million and a strategic pivot towards its Alector Brain Carrier (ABC) platform. This shift follows the discontinuation of its Phase 2 Alzheimer's trial for nivisnebart due to a futility analysis. The company maintains a cash runway expected to fund operations through at least 2027, focusing on advancing multiple preclinical ABC-enabled programs for neurodegenerative diseases.

$ALECMed

Alector (ALEC) CEO awarded 116,246 RSUs, boosts direct share stake

Alector, Inc. CEO Arnon Rosenthal was granted 116,246 restricted stock units (RSUs) on March 13, 2026, as equity compensation. These RSUs, which have no cash cost, will vest in two equal installments on September 1, 2026, and March 1, 2027. This grant increases his direct ownership to 2,454,422 common shares, in addition to indirect holdings through family trusts.

$ALECMed

Alector (ALEC) Appoints Neil Berkley as CFO

Alector (ALEC) has appointed Neil Berkley as Chief Financial Officer, effective December 10, 2025, while he will also retain his responsibilities as Chief Business Officer. The biotechnology company, which focuses on neurodegenerative therapies, faces significant financial challenges including negative margins and declining revenue growth. Despite a stable liquidity position, an Altman Z-Score of -3.61 indicates potential bankruptcy risk, and recent insider activity shows substantial selling with no buying.